# Study to Compare the Efficacy and Safety of F-627 and GRAN®

> **NCT04174599** · PHASE3 · COMPLETED · sponsor: **EVIVE Biotechnology** · enrollment: 242 (actual)

## Conditions studied

- Breast Cancer
- Neutropenia

## Interventions

- **DRUG:** F-627
- **DRUG:** GRAN®

## Key facts

- **NCT ID:** NCT04174599
- **Lead sponsor:** EVIVE Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-12
- **Primary completion:** 2019-01-24
- **Final completion:** 2019-06-19
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2025-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04174599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04174599, "Study to Compare the Efficacy and Safety of F-627 and GRAN®". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04174599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*